Vaccine durability and long-term protection from infection depend not just on whether antibodies are made, but on how long plasma cells survive in the bone marrow to keep making them. That survival question has been extraordinarily difficult to study in living humans — until now.
Using a microvascularized, perfusable human bone marrow-on-a-chip (hBMOC) platform, researchers integrated immune organoid-derived antibody-secreting cells (ASCs) into a three-dimensional model containing both endosteal and perivascular bone marrow subniches. The system revealed that human ASCs migrate through vessel walls and preferentially accumulate in perivascular zones, where they cluster near critical survival-promoting factors. Crucially, the presence of the endosteal niche — the region adjacent to bone surfaces — substantially altered ASC survival rates, migratory behavior, and retention, indicating that subniche crosstalk actively governs plasma cell fate. A distinct subset of ASCs exhibited a dynamic stop-and-go locomotion pattern, partially controlled by CXCR4-CXCL12 chemokine signaling, a pathway already implicated in hematopoietic stem cell trafficking.
This work addresses a longstanding translational gap: the overwhelming majority of plasma cell biology has been derived from murine models, which differ meaningfully from humans in marrow architecture, immune kinetics, and niche composition. The chip-based approach offers spatial resolution and real-time observability that neither animal models nor static human tissue samples can provide. For longevity and immunology research, the implications are notable — understanding why some plasma cells persist for decades while others disappear within weeks could inform strategies for improving vaccine durability, particularly in older adults whose bone marrow niches deteriorate with age. This is an incremental but methodologically significant advance: the hBMOC model itself may prove more valuable as a platform than any single finding it has yet produced, offering a reusable substrate for testing adjuvants, aging interventions, or plasma cell-targeting therapies in genuinely human biology.